Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a research report released on Monday, Benzinga reports. They currently have a $10.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Up 1.7 %

Shares of AUPH opened at $7.20 on Monday. The firm has a market cap of $1.03 billion, a P/E ratio of -16.74 and a beta of 1.44. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.05. The company’s 50-day moving average price is $6.18 and its 200 day moving average price is $5.59. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.01. The company had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.08) earnings per share. On average, sell-side analysts forecast that Aurinia Pharmaceuticals will post 0.13 earnings per share for the current year.

Insider Activity at Aurinia Pharmaceuticals

In related news, insider Scott Michael Habig sold 18,249 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares of the company’s stock, valued at $2,423,154.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Large investors have recently modified their holdings of the company. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $30,000. Tidemark LLC purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $39,000. Banque Cantonale Vaudoise increased its position in shares of Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 5,410 shares in the last quarter. Eagle Asset Management Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at $92,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter valued at $84,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.